Literature DB >> 21102559

Anterograde axonal transport of AAV2-GDNF in rat basal ganglia.

Agnieszka Ciesielska1, Gabriele Mittermeyer, Piotr Hadaczek, Adrian P Kells, John Forsayeth, Krystof S Bankiewicz.   

Abstract

We elucidated the effects of parkinsonian degeneration on trafficking of AAV2-GDNF in the nigro-striatum (nigro-ST) of unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats. Vector infused into striatum (ST) was transported to substantia nigra (SN), both pars compacta (SNc), and pars reticulata (SNr). In the lesioned hemisphere, glial cell line-derived neurotrophic factor (GDNF) immunoreactivity was only found in SNr consistent with elimination of SNc dopaminergic (DA) neurons by 6-OHDA. Further analysis showed that striatal delivery of AAV2-GDNF resulted in GDNF expression in globus pallidus (GP), entopeduncular nucleus (EPN), and subthalamic nucleus (STN) in both lesioned and unlesioned hemispheres. Injection of vector into SN, covering both SNc and SNr, resulted in striatal expression of GDNF in the unlesioned hemisphere but not in the lesioned hemisphere. No expression was seen in GP or EPN. We conclude that adeno-associated virus serotype 2 (AAV2) is transported throughout the nigro-ST exclusively by anterograde transport. This transport phenomenon directs GDNF expression throughout the basal ganglia in regions that are adversely affected in Parkinson's disease (PD) in addition to SNc. Delivery of vector to SN, however, does not direct expression of GDNF in ST, EPN, or GP. On this basis, we believe that striatal delivery of AAV2-GDNF is the preferred course of action for trophic rescue of DA function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21102559      PMCID: PMC3098627          DOI: 10.1038/mt.2010.248

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  38 in total

1.  Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.

Authors:  Clare E Thomas; Theresa A Storm; Zan Huang; Mark A Kay
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease.

Authors:  Marco A Passini; Shannon L Macauley; Michael R Huff; Tatyana V Taksir; Jie Bu; I-Huan Wu; Peter A Piepenhagen; James C Dodge; Lamya S Shihabuddin; Catherine R O'Riordan; Edward H Schuchman; Gregory R Stewart
Journal:  Mol Ther       Date:  2005-05       Impact factor: 11.454

Review 3.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

4.  Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

Authors:  U Ungerstedt
Journal:  Acta Physiol Scand Suppl       Date:  1971

5.  Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain.

Authors:  Piotr Hadaczek; Hanna Mirek; John Bringas; Janet Cunningham; Krys Bankiewicz
Journal:  Hum Gene Ther       Date:  2004-05       Impact factor: 5.695

6.  Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats.

Authors:  Andreas Arvidsson; Deniz Kirik; Cecilia Lundberg; Ronald J Mandel; Gunnar Andsberg; Zaal Kokaia; Olle Lindvall
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

7.  Expression of GDNF family receptor components during development: implications in the mechanisms of interaction.

Authors:  T Yu; S Scully; Y Yu; G M Fox; S Jing; R Zhou
Journal:  J Neurosci       Date:  1998-06-15       Impact factor: 6.167

Review 8.  Neuroprotective and neurorestorative properties of GDNF.

Authors:  D M Gash; Z Zhang; G Gerhardt
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

9.  Adeno-associated virus vectors can be efficiently produced without helper virus.

Authors:  T Matsushita; S Elliger; C Elliger; G Podsakoff; L Villarreal; G J Kurtzman; Y Iwaki; P Colosi
Journal:  Gene Ther       Date:  1998-07       Impact factor: 5.250

10.  Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

Authors:  Brian K Kaspar; Jerònia Lladó; Nushin Sherkat; Jeffrey D Rothstein; Fred H Gage
Journal:  Science       Date:  2003-08-08       Impact factor: 47.728

View more
  36 in total

Review 1.  Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.

Authors:  Rachel J Sizemore; Sonja Seeger-Armbruster; Stephanie M Hughes; Louise C Parr-Brownlie
Journal:  J Neurophysiol       Date:  2016-02-17       Impact factor: 2.714

2.  Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.

Authors:  Sara E Gombash; Jack W Lipton; Timothy J Collier; Lalitha Madhavan; Kathy Steece-Collier; Allyson Cole-Strauss; Brian T Terpstra; Anne L Spieles-Engemann; Brian F Daley; Susan L Wohlgenant; Valerie B Thompson; Fredric P Manfredsson; Ronald J Mandel; Caryl E Sortwell
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

3.  Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.

Authors:  Luis Quintino; Giuseppe Manfré; Erika Elgstrand Wettergren; Angrit Namislo; Christina Isaksson; Cecilia Lundberg
Journal:  Mol Ther       Date:  2013-07-24       Impact factor: 11.454

Review 4.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

5.  Transgene expression in target-defined neuron populations mediated by retrograde infection with adeno-associated viral vectors.

Authors:  Markus Rothermel; Daniela Brunert; Christine Zabawa; Marta Díaz-Quesada; Matt Wachowiak
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

Review 6.  Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.

Authors:  Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurobiol Dis       Date:  2011-10-14       Impact factor: 5.996

7.  Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.

Authors:  Waldy San Sebastian; R Mark Richardson; Adrian P Kells; Clementine Lamarre; John Bringas; Philip Pivirotto; Ernesto A Salegio; Stephen J Dearmond; John Forsayeth; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

8.  Cypermethrin-induced nigrostriatal dopaminergic neurodegeneration alters the mitochondrial function: a proteomics study.

Authors:  Sonal Agrawal; Ashish Singh; Pratibha Tripathi; Manisha Mishra; Pradhyumna Kumar Singh; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2014-04-24       Impact factor: 5.590

9.  Moving forward toward a cure for Parkinson's: neuropathology of the nigrostriatal pathway determines the location of growth factor delivery.

Authors:  Terence R Flotte; Robert M Frederickson; Pedro R Lowenstein; Christian Mueller
Journal:  Mol Ther       Date:  2011-05       Impact factor: 11.454

Review 10.  Convection-Enhanced Delivery.

Authors:  A M Mehta; A M Sonabend; J N Bruce
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.